Why the study?
How should low-molecular-weight heparins be managed in patients with renal insufficiency?
How should low-molecular-weight heparins be managed in patients with renal insufficiency?
LMWH can be used in patients with severe renal insufficiency if anti-Xa levels are monitored and doses are adjusted, though UFH is preferred in unstable patients or those with high bleeding risk.
No takes yet. Share an insight, caveat, or question.
Cautious LMWH use with anti-Xa monitoring may be feasible in severe RI; leaves open need for RCTs to confirm safety and protocols.
A 2009 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: